NEW YORK (GenomeWeb News) – Mizuho Securities has initiated coverage of Fluidigm and BG Medicine, placing a Buy rating on both firms.

For Fluidigm, Mizuho analyst Peter Lawson has placed a $17 price target on the firm's stock, a roughly 11 percent premium to Thursday's closing price of $15.28.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.